Therapeutic Strategies
18 records.
Strategy ID | Strategy | Other Terms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S01 | anti-apoptosis | Anti-inflammatory; Anti-apoptosis; Anti-oxidative stress; Anti-inflammatory; Anti-apoptosis; Anti-apoptosis; Anti-apoptosis; Anti-oxidative stress; Anti-inflammatory; inducing apoptosis in those cells; Anti-fibrosis; Anti-inflammatory; Anti-apoptosis; Anti-inflammatory; Anti-oxidative stress; Anti-apoptosis; Anti-apoptosis; Enhance lipid metabolism; Anti-oxidative stress; Anti-fibrosis; Anti-apoptosis; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Anti-oxidative stress; Anti-apoptosis; Anti-fibrosis; Anti-apoptosis | MAPK; caspase-3; Bcl-2; TNF-α; IL-1β; IL-6; podocin; nephrin; IL-1β; IL-6; TNF-α; HO-1; NF-κB; VDR; p38 MAPK; NF-κB; PPAR; AMPK; AMPK; NOX4; caspase-3; NOX4; ERK; Bcl-2; Nrf2; p53; Smad2/3; NOX4 | streptozotocin; Oleuropein; NS-398; iN/i-acetylcysteine; aminoguanidine; metformin; l-cysteine; Astragalus; Salvia miltrorrhiza; Polygala fallax Hemsl; compound Sanqi granules; metformin; Okadaic acid; miR-218 inhibitor; Gushen Jiedu capsule; Hirudin; Akebia saponin D; STZ; calcitriol; streptozocin; 1,25-dihydroxyvitamin D3; anisomycin; Echinacoside; PDTC; fenofibrate; miRNA antagomiR; dencichine; canagliflozin; isoprenaline; streptozotocin; recombinant human clusterin protein; Chloroquine; Amodiaquine; Streptozotocin; angiotensin II; calycosin; mitoquinone; ML385; Calcium dobesilate; FK506; SIS3; Forskolin; recombinant thrombomodulin | Details |
S02 | anti-fibrosis | Anti-fibrosis; Anti-hypertensive; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-fibrosis; Anti-inflammatory; Anti-fibrosis; anti-fibrosis; Anti-inflammatory; Anti-oxidative stress; Anti-fibrosis; Anti-fibrosis; Enhance lipid metabolism; Enhance lipid metabolism; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Improve insulin resistance; Enhance lipid metabolism; Regulating intestinal flora; Anti-fibrosis; Anti-fibrosis; Anti-inflammatory; Anti-apoptosis; Anti-hypertensive; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-fibrosis; Anti-fibrosis; Enhance lipid metabolism; Improve insulin resistance; Anti-inflammatory; Anti-fibrosis; Enhance lipid metabolism; Anti-fibrosis; Anti-inflammatory; Anti-oxidative stress; Anti-fibrosis; Anti-apoptosis; Cell therapy; Anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Cell therapy; Anti-fibrosis; Improve insulin resistance; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-fibrosis; Anti-inflammatory; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Anti-fibrosis; Anti-inflammatory; Anti-oxidative stress; Anti-fibrosis; Anti-apoptosis; Enhance lipid metabolism; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-oxidative stress; Anti-lipogenesis; Anti-fibrosis | HIF; FGF23; MAPK; Nrf2; HO-1; p38 MAPK; JNK; PPAR; FXR; Smad2/3; Smad2/3; TLR4; Smad2/3; Wnt/β-catenin; Smad2/3; Smad4; TGF-β; IL-1β; IL-6; TNF-α; ACE; Smad4; PKD1; p62; mTOR; TNF-α; TLR4; TGF-β; erythropoietin receptor; MMP-9; TLR4; IL-2; IL-24; IL-2; NOX4; MAPK; ACE; NF-κB; STAT3; JAK2; NOX4; NF-κB; Nrf2; SGLT2; HIF; Smad2/3; NF-κB; AMPK; mTOR; ERK; MAPK; AMPK; IL-6; IL-1β; TNF-α; TGF-β; EGF; RAGE; Wnt/β-catenin; AKT; AMPK; NOX4; caspase-3; NLRP3; NLRP3; NF-κB; Smad2/3; Smad2/3; p38 MAPK; p53 | riociguat; sGC stimulators; sGC activators; MRI-1867; JD5037; 1400W; HIF-PH inhibitors; paricalcitol; LNA-anti-miR-150; scrambled LNA; Ganoderic acid; GA-A; BML-111; ML385; traditional medicine; saikosaponin B2; miR-9-5p; cisplatin; CP; obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid); tropifexor; nidufexor; mdivi-1; silibinin; lisinopril; MK-521; Adriamycin; 2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione; NOX5 siRNA; ICG-001; IC-2; IC-2-506-1; IC-2-506-2; IC-2-506-3; IC-2-Ar-Cl; IC-2-OH; IC-2-OTBS; IC-2-F; Rehmannia glutinosa leaves total glycoside; glucose; glucosamine; streptozotocin; Low molecular weight fucoidan; protamine sulfate; propionate; Hirudin; Hsub2/subS; NO; Hsub2/subSxa0; xa0; NO; angiotensin-converting enzyme inhibitors; angiotensin II receptor blockers; N-acetyl-seryl-aspartyl-lysyl-proline; USC; Korean red ginseng; Panax ginseng C.A. Mey.; streptozotocin; dapagliflozin; losartan; Bisphosphonates; RIS; recombinant human soluble thrombomodulin; deacetylase inhibitors; Human recombinant erythropoietin; rEPO; Huangkui capsule; 1,25sub2/subDsub3/sub; Danggui-Shaoyao-San; IL-24; Jiawei Shuilu Erxiandan; Coptis; CH5451098; MRS1754; Retinoic acid; ACE inhibitors; ATsub1/sub receptor antagonists; N-acetyl-seryl-aspartyl-lysyl-proline; glycolysis inhibitors; prolyl oligopeptidase inhibitor S17092; imidapril; TA-606; Baicalin; β-Caryophyllene; dapagliflozin; streptozocin; fosinopril; valsartan; Chrysophanol; Plantamajoside; miR-101a-3p; miR-101; Am80; all-trans retinoic acid; Ginsenoside Rb1; rapamycin; Akt inhibitor; metformin; p38-MAPK inhibitor; ERK-MAPK inhibitor; psoralen; GLP-1RAs; liraglutide; XAV-939; streptozocin; TGF-x3b2; 1; dencichine; streptozotocin; genistein; Streptozotocin; transforming growth factor-x3b2; 1; paramylon; streptozotocin; C-peptide; SKF96365; TRPC6-siRNA; NFAT2-siRNA; ICG-001; short-chain fatty acids; acetate; propionate; butyrate; GPR43 agonist; TRAIL; PF429242; liraglutide; enalapril; canagliflozin; isoprenaline; Liuwei Dihuang pill; streptozotocin; six novel poricoic acids from Poria cocos; poricoic acid ZM; poricoic acid ZP; secolanostane tetracyclic triterpenoids; emodin; HGF; traditional Chinese medicine; Western medicine therapies; Sauchinone; Shenkang VII recipe; rhEPO; MOCK-MPs; hEPO-MPs; Calcium dobesilate; topiroxostat; siXDH; Ginkgo biloba extract; Streptozotocin; recombinant thrombomodulin | Details |
S03 | anti-inflammatory | Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Immunotherapy; Anti-inflammatory; Anti-apoptosis; Anti-inflammatory; Anti-inflammatory; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-apoptosis; Anti-inflammatory; Anti-oxidative stress; Anti-fibrosis; Enhance lipid metabolism; Anti-inflammatory; Anti-fibrosis; Enhance lipid metabolism; Anti-inflammatory; Anti-inflammatory; Immunosuppressive; Anti-inflammatory; inducing apoptosis in those cells; Anti-inflammatory; Improve insulin resistance; Enhance lipid metabolism; Regulating intestinal flora; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Improve insulin resistance; Enhance lipid metabolism; Anti-inflammatory; anti-inflammatory; anti-oxidative stress; Anti-fibrosis; Anti-inflammatory; Anti-apoptosis; Anti-hypertensive; Anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Immunotherapy; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-inflammatory; Improve insulin resistance; Anti-inflammatory; Anti-oxidative stress; Anti-apoptosis; Anti-hypertensive; Anti-inflammatory; Anti-inflammatory; Lifestyle measures; non-steroidal anti-inflammatory agents (NSAIDs); Anti-inflammatory; Anti-fibrosis; Enhance lipid metabolism; Regulating intestinal flora; Improve insulin resistance; Enhance lipid metabolism; Anti-inflammatory; Enhance lipid metabolism; Anti-oxidative stress; Anti-inflammatory; anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Cell therapy; Anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Immunotherapy; Anti-inflammatory; Improve insulin resistance; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; non-steroidal anti-inflammatory drugs (NSAIDs) treatment; Anti-fibrosis; Anti-inflammatory; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Anti-fibrosis; Anti-inflammatory; Anti-oxidative stress; Anti-inflammatory renoprotection; anti-inflammatory effect; Enhance lipid metabolism; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-oxidative stress; Anti-lipogenesis; Anti-fibrosis | NF-κB; TNF-α; NF-κB; FGF23; MAPK; caspase-3; Bcl-2; Nrf2; HO-1; p38 MAPK; JNK; FXR; TNF-α; IL-1β; IL-6; AMPK; PPAR; IL-1β; IL-6; TNF-α; ACE; Smad4; PKD1; p62; mTOR; AMPK; HIF; HIF; Smad2/3; Smad2/3; VEGFA; IL-6; MAPK; IL-1β; EGFR; TLR4; IL-6; Wnt/β-catenin; HO-1; NF-κB; TLR4; NF-κB; NF-κB; STAT3; JAK2; NOX4; NF-κB; Nrf2; SGLT2; HIF; SIRT1; JAK1; JAK2; TLR4; Smad2/3; IL-17; IL-6; PI3K; AKT; IL-6; IL-1β; TNF-α; TGF-β; EGF; IL-17; AMPK; NOX4; caspase-3; NOX4; NLRP3; caspase-1; IL-1β; ERK; JNK; p38 MAPK; NLRP3; NLRP3; NF-κB; HIF; hepcidin | MRI-1867; JD5037; 1400W; prednisolone; methotrexate; eldecalcitol; teriparatide; denosumab; streptozotocin; chloroquine; dexamethasone; 5-aminosalicylates; azathioprine; methotrexate; Glatiramer acetate; Glatiramer; paricalcitol; Oleuropein; methyl corosolate; uvaol; oleanolic acid; phenolic-rich açaí seed extract; BML-111; ML385; Recombinant thrombomodulin; obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid); tropifexor; nidufexor; Tripterygium wilfordii Hook F; C4BP(x3b2; -); cyclophosphamide; methylprednisolone; cyclophosphamide; tripterygium wilfordii multiglycosides; prednisone; Astragalus; Salvia miltrorrhiza; Polygala fallax Hemsl; compound Sanqi granules; metformin; Okadaic acid; berberine; NOX5 siRNA; Tectorigenin; gentamicin; miR-218 inhibitor; methylprednisolone; prednisolone; mycophenolate mofetil; cyclosporine A; cyclophosphamide; rituximab; azathioprine; tacrolimus; propionate; Hirudin; Hsub2/subS; NO; Hsub2/subSxa0; xa0; NO; USC; prednisolone; mizoribine; angiotensin-converting enzyme inhibitors; steroids; cyclophosphamide; Korean red ginseng; Panax ginseng C.A. Mey.; streptozotocin; probiotics; Lactobacillus; Bifidobacterium; Sodium-glucose cotransporter 2 inhibitors; SGLT2 inhibitors; intravenous immunoglobulins; glucocorticoids; cyclophosphamide; azathioprine; Cyanidin-3-glucoside; Curcumin; quercetin; formononetin; calycosin; 7-O-methylisomucronulatol; quercetin; 1,25sub2/subDsub3/sub; parthenolide; insulin; Tocilizumab; Oral prednisolone; Astragaloside IV; Akebia saponin D; dioscin; streptozocin; Baicalin; tegafur/gimeracil/oteracil; furosemide; prednisolone; methylprednisolone; prednisolone; steroid; allopurinol; β-Caryophyllene; Colchicine; systemic/intra-articular corticosteroids; non-steroidal anti-inflammatory agents; IL-1 inhibitors; immunosuppressive therapy; STZ; dapagliflozin; streptozocin; Ergosterol; Streptozotocin; corticosteroids; cyclophosphamide; tofacitinib; inulin; Sodium-glucose cotransporter 2 inhibitors; curcumin; camptothecin; streptomycin; JAK inhibitors; ruxolitinib; Plantamajoside; methylprednisolone; intravenous immunoglobulin; vitamin D receptor agonists; paricalcitol; Am80; all-trans retinoic acid; Capsicum annuum L.; HPMA copolymer-based dexamethasone prodrug; PEG-based dexamethasone prodrug; glucocorticoid; cyclophosphamide; psoralen; Caffeine; glucocorticoids; Streptozotocin; paramylon; Campath; IV steroid; IV antibiotics; clindamycin; cMet agonistic antibody; short-chain fatty acids; acetate; propionate; butyrate; GPR43 agonist; Infliximab; corticosteroids; secukinumab; prednisolone; methylprednisolone; Cyclophosphamide; non-steroidal anti-inflammatory drugs; methotrexate; steroid; Dexamethasone; Tiliacora triandra extract; 5,7-dihydroxy-6-oxoheptadecanoic acid; liraglutide; enalapril; canagliflozin; isoprenaline; Liuwei Dihuang pill; streptozotocin; six novel poricoic acids from Poria cocos; poricoic acid ZM; poricoic acid ZP; secolanostane tetracyclic triterpenoids; Chuanxiong Rhizoma; Myricanone; Wallichilide; Sitosterol; Chloroquine; Amodiaquine; Streptozotocin; statins; atorvastatin; Allopurinol; febuxostat; Terminalia bellerica; saxagliptin; Adriamycin; baru almond oil; mineral oil; Epicatechin; 2,3-dihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid; 3-hydroxyphenylpropionic acid; Sauchinone; Shenkang VII recipe; porcine collagen hydrolysate; prolyl-hydroxyproline; APX-115; sodium nitrite; isoquercetin; topiroxostat; siXDH; Ginkgo biloba extract; Streptozotocin | Details |
S04 | anti-lipogenesis | Enhance lipid metabolism; Anti-lipogenesis; Anti-inflammatory; Anti-oxidative stress; Anti-lipogenesis; Anti-fibrosis | AMPK | Liraglutide; Ginkgo biloba extract; Streptozotocin | Details |
S05 | anti-oxidative stress | Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-oxidative stress; Enhance lipid metabolism; Improve insulin resistance; Anti-oxidative stress; Anti-oxidative stress; Anti-oxidative stress; Anti-inflammatory; Anti-apoptosis; Anti-inflammatory; Anti-oxidative stress; Anti-fibrosis; Anti-apoptosis; Anti-oxidative stress; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; anti-inflammatory; anti-oxidative stress; Anti-oxidative stress; Anti-inflammatory; Anti-inflammatory; Anti-oxidative stress; Anti-apoptosis; Anti-oxidative stress; Anti-fibrosis; Enhance lipid metabolism; Anti-oxidative stress; Anti-inflammatory; Anti-oxidative stress; Anti-fibrosis; Anti-apoptosis; Anti-oxidative stress (Epigallocatechin-3-gallate (EGCG) activates Nrf2/ARE signaling pathway by downregulating Keap1 and boosting nuclear Nrf2 level); Anti-hypertensive; Anti-oxidative stress; Improve insulin resistance; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Anti-oxidative stress; Anti-apoptosis; Anti-fibrosis; Anti-inflammatory; Anti-oxidative stress; relieving oxidative stress; Enhance lipid metabolism; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-oxidative stress; Anti-lipogenesis; Anti-fibrosis | TNF-α; NF-κB; MAPK; caspase-3; Bcl-2; DPP4; Nrf2; HO-1; p38 MAPK; JNK; SGLT2; mineralocorticoid receptor; MMP-9; AMPK; HIF; HIF; Smad2/3; Smad2/3; VEGFA; IL-6; MAPK; IL-1β; EGFR; Wnt/β-catenin; HO-1; NF-κB; NOX4; MAPK; NF-κB; STAT3; JAK2; NOX4; NF-κB; Nrf2; NF-κB; NOX4; SIRT1; AMPK; Nrf2; AMPK; NOX4; caspase-3; ERK; JNK; p38 MAPK; NLRP3; NLRP3; NF-κB; AMPK; AMPK; Bcl-2; Nrf2; Smad2/3; NOX4 | MRI-1867; JD5037; 1400W; Glatiramer acetate; Glatiramer; Berberine; GKT137831; febuxostat; topiroxostat; Oleuropein; Resveratrol; Dipeptidyl peptidase-4 inhibitors; alogliptin; saxagliptin; sitagliptin; teneligliptin; phenolic-rich açaí seed extract; BML-111; ML385; empagliflozin; dapagliflozin; ramipril; hydro-chloro-thiazide; iN/i-acetylcysteine; aminoguanidine; metformin; l-cysteine; NOX5 siRNA; gentamicin; syringic acid; streptozotocin; tamarind seed coat ethanol extract; Finerenone; USC; probiotics; Lactobacillus; Bifidobacterium; Sodium-glucose cotransporter 2 inhibitors; SGLT2 inhibitors; Cyanidin-3-glucoside; N-acetylcysteine; quercetin; formononetin; calycosin; 7-O-methylisomucronulatol; quercetin; streptozotocin; Astragaloside IV; Akebia saponin D; Retinoic acid; Folic acid; N-acetyl-cysteine; Baicalin; β-Caryophyllene; Ergosterol; Streptozotocin; GKT137831; GKT13783; Sodium-glucose cotransporter 2 inhibitors; Plantamajoside; Capsicum annuum L.; dencichine; reactive oxygen species scavenger; Ang II receptor blockers; Epigallocatechin-3-gallate; type 1 angiotensin II receptor blockade; olmesartan; short-chain fatty acids; acetate; propionate; butyrate; GPR43 agonist; Tiliacora triandra extract; 5,7-dihydroxy-6-oxoheptadecanoic acid; canagliflozin; isoprenaline; streptozotocin; recombinant human clusterin protein; six novel poricoic acids from Poria cocos; poricoic acid ZM; poricoic acid ZP; secolanostane tetracyclic triterpenoids; Chloroquine; Amodiaquine; Streptozotocin; Allopurinol; febuxostat; Terminalia bellerica; Epicatechin; 2,3-dihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid; 3-hydroxyphenylpropionic acid; Sauchinone; GLP-1; liraglutide; exendin-4; Cinacalcet; mitoquinone; ML385; sodium nitrite; isoquercetin; vitamin E; selenium; SIS3; Forskolin; topiroxostat; siXDH; Ginkgo biloba extract; Streptozotocin; puromycin aminonucleoside; amiloride | Details |
S06 | anti-platelet aggregation | Percutaneous left atrial appendage occlusion (LAAO); Antiplatelet therapy; Anti-platelet aggregation; antiplatelet therapy; Anti-hypertensive; Anti-platelet aggregation; Anti-platelet aggregation; Enhance lipid metabolism; platelet-rich plasma injections (PRP); Antiplatelet treatment; Anti-hypertensive; Enhance lipid metabolism; Anti-platelet aggregation; Enhance lipid metabolism; Anti-platelet aggregation | oral anticoagulation; antiplatelet therapy; clopidogrel; OAC therapy; antiplatelet therapy; ticagrelor; aspirin; antiplatelet therapy; beraprost; cinacalcet; lanthanum carbonate; Amiodarone; Ticagrelor; Clopidogrel; antithrombotic agents; single antiplatelet therapy; dual antiplatelet; anticoagulation and antiplatelet; anticoagulation monotherapy; antihypertensive agents; antithrombotics; antianemics; proton pump inhibitors; allopurinol; rilmenidine; long-term benzodiazepines; anticholinergic drugs; hydroxyzine; insulin; dual antiplatelet therapy; statins; beta-blockers; prasugrel; clopidogrel; aspirin; non-steroid antiinflamatory drugs; platelet-rich plasma injections; warfarin; direct acting oral anticoagulant; bivalirudin; DOACs; warfarin; APT; antithrombotic therapy; antithrombotic agents; antiplatelet therapy; captopril; tiopronin; active form of dalcetrapib; active metabolite of prasugrel, R-138727; aspirin; clopidogrel; prasugrel; ticagrelor; rivaroxaban; statins | Details | |
S07 | antihypertensive | Anti-fibrosis; Anti-hypertensive; Anti-hypertensive; antihypertensive medications; multidrug combination antihypertensive treatment; empirical addition (or increase in the dose) of an antihypertensive agent of a different class""; Anti-hypertensive; Lifestyle measures; Anti-inflammatory; Improve insulin resistance; Enhance lipid metabolism; Regulating intestinal flora; Anti-hypertensive; Anti-hypertensive; Anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Immunotherapy; Anti-hypertensive; Immunosuppressive treatment; Anti-hypertensive; Anti-hypertensive; Anti-platelet aggregation; other antihypertensive drugs; antihypertensive therapy; Anti-hypertensive; Anti-inflammatory; Anti-hypertensive (standard antihypertensive treatment; intensive antihypertensive treatment); Blood pressure management; Anti-hypertensive; Enhance lipid metabolism; Anti-hypertensive; Enhance lipid metabolism; Anti-platelet aggregation; Improve insulin resistance; Anti-hypertensive; Anti-hypertensive; Anti-oxidative stress; antihypertensives; Lifestyle measures; Anti-hypertensive; Anti-fibrosis; Anti-inflammatory; Anti-hypertensive | ACE; Smad4; PKD1; angiotensin receptor; SGLT2; angiotensin II receptor; mineralocorticoid receptor; ACE | riociguat; sGC stimulators; sGC activators; antihypertensive medications; carvedilol; lercanidipine; enalapril; folic acid; retinoic acid; angiotensin II; antihypertensive drug; Tripterygium Wilfordii Hook F; valsartan; Renin-angiotensin system inhibitors; diuretics; calcium channel blocker; corticosteroid; anti-hypertensive treatment; NSAIDs; naproxen; celecoxib; proton pump inhibitor; non-selective NSAID; selective cyclo-oxygenase-2 inhibitor; renin-angiotensin system blockers; antihypertensive agent; cilnidipine; valsartan; RAAS-is; steroids; immunosuppressors; amiloride; hydrochlorothiazide; berberine; Aliskiren; calcium channel blocker; angiotensin II receptor blocker; ARB; Chlorthalidone; Hydrochlorothiazide; Hsub2/subS; NO; Hsub2/subSxa0; xa0; NO; prednisolone; mizoribine; angiotensin-converting enzyme inhibitors; ACEI; eculizumab; antihypertensive agents; antithrombotics; antianemics; proton pump inhibitors; allopurinol; rilmenidine; long-term benzodiazepines; anticholinergic drugs; hydroxyzine; Qian Yang Yu Yin Granule; RAAS blockers; other antihypertensive drugs; antihypertensives; antihypertensive classes; antihypertensive therapy; melatonin; RAASi; Aliskiren; ARBs; ACEIs; tegafur/gimeracil/oteracil; furosemide; prednisolone; angiotensin receptor blockers; valsartan; antihypertensive drugs; fosinopril; valsartan; Canagliflozin; sodium glucose co-transporter 2 inhibitors; Aspirin; Antihypertensive; Lipid-Lowering Treatment; Sodium-glucose cotransporter 2 inhibitors; angiotensin II receptor blocker; Spironolactone; KBP-5074; captopril; enalaprilate; lisinopril; losartan; valsartan; furosemide; pravastatin; simvastatin; Renin Angiotensin System inhibitors; ACE inhibitors; diuretics; β-blockers; Thiazide diuretics; dihydropyridine calcium-channel blockers; angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; calcium-channel blockers; thiazide-like diuretics; lisinopril; Edarbyclor; azilsartan medoxomil; chlorthalidone; hydrochlorothiazide; aliskiren; ARB; enalapril; non-steroidalanti-inflammatory drugs; antihypertensive treatment; Chlorthalidone; loop diuretics; angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; statin; captopril; tiopronin; active form of dalcetrapib; active metabolite of prasugrel, R-138727; Liuwei Dihuang pills; metformin hydrochloride sustained-release tablets; irbesartan tablets; renin-angiotensin-aldosterone system inhibitor; type 1 angiotensin II receptor blockade; olmesartan; steroid; immunosuppressive agents; enalapril; corticosteroid treatment; Angiotensin-converting-enzyme inhibitors; antihypertensives; GLP-1 receptor analogue; SGLT2-inhibitor; sacubitril/valsartan; valsartan; Sulodexide; liraglutide; enalapril; ACE-I/ARBs; angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers; labetalol; ACEi; ARB; ARBs | Details |
S08 | bariatric surgery | metabolic bariatric surgery; intensive lifestyle intervention | metformin; rosiglitazone; insulin | Details | |
S09 | cell therapy | high-dose melphalan/autologous peripheral blood stem cell transplantation; Cell therapy; Cell therapy; Anti-inflammatory; Anti-fibrosis; Cell therapy; Anti-fibrosis | B cells; IL-6; IL-1β; TNF-α; TGF-β; EGF; SIRT1 | chemotherapy; high-dose melphalan; melatonin; granulocyte-colony stimulating factor; metformin; Mesenchymal stem cells; Human gingiva derived MSCs; Streptozotocin; streptozotocin; C-peptide; SIRT1 activators | Details |
S10 | dialysis therapy | individualized dialysis machine temperature control; hemodialysis; hemodialysis (HD); peritoneal dialysis (PD); haemodialysis treatment; hypoxia-inducible factor prolyl hydroxylase inhibitor for dialysis-dependent CKD anemia; haemodialysis (HD); peritoneal dialysis (PD); conversion to hemodialysis; Hemodialysis; diet modifications; Hemodialysis; Peritoneal dialysis | HIF | dialysate-containing glucose; Cisplatin; Etoposide; gadolinium-based contrast agents; gadoteric acid; non-steroidal anti-inflammatory agent; 10 calcium gluconate; insulin; dextrose; salbutamol nebulization; sodium polystyrene sulfonate; roxadustat; darbepoetin alfa; iron; warfarin; bisphosphonate; sodium thiosulfate; unfractionated heparin; uric acid lowering drugs; 5-fluorouracil; leucovorin; 1.5 glucose; 2.3 glucose | Details |